As of June 06, 2026, Rocket Pharmaceuticals's top three insider holders are Investments, Lp Rtw (Director, 18.66Mn shares), Investments, Lp Rtw (Director, 18.19Mn shares), Roderick Wong (Director, 16.27Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Pedro P Granadillo | - | 54,734 | 0 | 18 Jul, 2025 |
| David P Southwell | - | 0 | 113,124 | 20 May, 2024 |
| Carsten Boess | - | 30,000 | 0 | 18 Jul, 2025 |
| Mikael Dolsten | - | 44,220 | 0 | 18 Jul, 2025 |
| Investments, Lp Rtw | - | 0 | 18,657,605 | 30 Aug, 2023 |
| Roderick Wong | - | 0 | 16,272,635 | 31 Aug, 2021 |
| Fady Ibraham Malik | - | 30,000 | 0 | 18 Jul, 2025 |
| John Militello | - | 91,019 | 0 | 20 Feb, 2026 |
| Martin Wilson | General Counsel | 682,000 | 0 | 20 Feb, 2026 |
| Gaurav Shah | Ceo | 1,046,055 | 0 | 20 Feb, 2026 |
| Kinnari Patel | Chief Operating Officer | 441,927 | 0 | 22 May, 2025 |
| Gotham Makker | - | 0 | 415,346 | 18 Jul, 2025 |
| Jonathan David Schwartz | Chief Medical Officer | 299,064 | 0 | 20 Nov, 2025 |
| Elisabeth Bjork | - | 50,000 | 0 | 06 Jan, 2026 |
| Syed Ali-Aamir Rizvi | Chief Medical Officer | 407,874 | 0 | 13 Feb, 2026 |
| Mark Andrew White | Chief Medical Officer | 76,662 | 0 | 12 Apr, 2023 |
| Aaron Ondrey | Chief Financial Officer | 128,173 | 0 | 08 Jul, 2025 |
| Piratip Pratumsuwan | - | 30,000 | 0 | 18 Jul, 2025 |
| Peter Fong | - | 53,333 | 0 | 03 Oct, 2025 |
| Sarbani Chaudhuri | - | 285,160 | 0 | 13 Feb, 2026 |
| Christopher James Stevens | Chief Operating Officer | 469,129 | 0 | 13 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 18 Feb, 2026 | Gaurav Shah | Common Stock | D | 5,990 | $3.34 | 1,046,055 | D | S |
| 18 Feb, 2026 | Martin Wilson | Common Stock | D | 1,376 | $3.34 | 682,000 | D | S |
| 18 Feb, 2026 | Martin Wilson | Common Stock | D | 1,376 | $3.34 | 682,000 | D | S |
| 18 Feb, 2026 | John Militello | Common Stock | D | 1,157 | $3.34 | 91,019 | D | S |
| 13 Feb, 2026 | John Militello | Common Stock | D | 3,726 | $3.31 | 92,176 | D | S |
| 13 Feb, 2026 | Martin Wilson | Common Stock | D | 12,253 | $3.31 | 683,376 | D | S |
| 13 Feb, 2026 | Gaurav Shah | Common Stock | D | 12,279 | $3.31 | 1,052,045 | D | S |
| 13 Feb, 2026 | Martin Wilson | Common Stock | D | 12,253 | $3.31 | 683,376 | D | S |
| 11 Feb, 2026 | Sarbani Chaudhuri | Common Stock | A | 125,924 | $0.00 | 285,160 | D | A |
| 11 Feb, 2026 | Martin Wilson | Common Stock | A | 311,813 | $0.00 | 695,629 | D | A |
| 11 Feb, 2026 | Syed Ali-Aamir Rizvi | Common Stock | A | 61,963 | $0.00 | 407,874 | D | A |
| 11 Feb, 2026 | Christopher James Stevens | Common Stock | A | 61,963 | $0.00 | 469,129 | D | A |
| 11 Feb, 2026 | Christopher James Stevens | Common Stock | A | 61,963 | $0.00 | 469,129 | D | A |
| 11 Feb, 2026 | Martin Wilson | Common Stock | A | 311,813 | $0.00 | 695,629 | D | A |
| 11 Feb, 2026 | John Militello | Common Stock | A | 29,982 | $0.00 | 95,902 | D | A |
| 11 Feb, 2026 | Syed Ali-Aamir Rizvi | Common Stock | A | 61,963 | $0.00 | 407,874 | D | A |
| 11 Feb, 2026 | Gaurav Shah | Common Stock | A | 286,028 | $0.00 | 1,064,324 | D | A |
| 11 Feb, 2026 | Martin Wilson | Stock Option (Right to Buy) | A | 468,187 | $0.00 | 468,187 | D | A |
| 11 Feb, 2026 | Christopher James Stevens | Stock Option (Right to Buy) | A | 93,037 | $0.00 | 93,037 | D | A |
| 11 Feb, 2026 | Sarbani Chaudhuri | Stock Option (Right to Buy) | A | 189,076 | $0.00 | 189,076 | D | A |